Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes

Código QR

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes

João Coelho1, Luísa Malheiro1, João Melo Beirão1,2, Angelina Meireles1,2, Bernardete Pessoa1,2 1Unit of Ophthalmology, Centro Hospitalar Universitário Do Porto, Porto, Portugal; 2Unit of Ophthalmology, Universidade Do Porto-Instituto Ci&ecir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Coelho J, Malheiro L, Melo Beirão J, Meireles A, Pessoa B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	diabetic macular edema fluocinolone acetonide dexamethasone implant intravitreal implants real-world vitrectomy Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/7d332ae5de2a45b99615deb965cb1585
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE
por: Elbarky AM
Publicado: (2020)

Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up
por: Kubaisi B, et al.
Publicado: (2018)

Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
por: Massin P, et al.
Publicado: (2016)

Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
por: Zarranz-Ventura J, et al.
Publicado: (2020)

Comment on ’Effectiveness of 190 μg Fluocinolone Acetonide versus 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis’ [Response to Letter]
por: Zarranz-Ventura J, et al.
Publicado: (2020)

Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
por: Steeples LR, et al.
Publicado: (2021)

Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
por: Adán A, et al.
Publicado: (2020)

Real-World Outcomes in Diabetic Macular Edema for the 0.2 μg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK
por: Mushtaq B, et al.
Publicado: (2021)

Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
por: Saedon H, et al.
Publicado: (2017)

Letter to the Editor Regarding the “Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The Constant Analysis” Article [Letter]
por: Taylor K, et al.
Publicado: (2020)

Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective
por: Urbančič M, et al.
Publicado: (2019)

A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome
por: Vadalà M, et al.
Publicado: (2020)

Update on corticosteroids for diabetic macular edema
por: Schwartz SG, et al.
Publicado: (2016)

Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy
por: Wallsh J, et al.
Publicado: (2016)

Dexamethasone Intravitreal Implant for the Treatment of Macular Edema Following Retinal Vein Occlusion: Post Hoc Analysis of Post-Marketing Surveillance Data in the Real-World Setting in Korea
por: Kim MS, et al.
Publicado: (2021)

Effects of Repeated Intravitreal Injections of Dexamethasone Implants on Intraocular Pressure: A 4-Year Study
por: Pacella E, et al.
Publicado: (2020)

Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex® Outcomes
por: Udaondo P, et al.
Publicado: (2021)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
por: Kaya C, et al.
Publicado: (2019)

Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization
por: Figueira J, et al.
Publicado: (2021)

Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema
por: Pessoa B, et al.
Publicado: (2021)

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
por: Hall J
Publicado: (2016)

Usefulness of anti-vascular endothelial growth factor combined with dexamethasone implant for retinal vein occlusion
por: Kim M
Publicado: (2016)

Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone
por: Zola M, et al.
Publicado: (2017)

Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
por: Cham A, et al.
Publicado: (2016)

Comparison of Posterior Hyaloid Assessment Using Preoperative Optical Coherence Tomography and Intraoperative Triamcinolone Acetonide Staining During Vitrectomy
por: Albabtain B, et al.
Publicado: (2021)

Macular edema resolution assessment with implantable dexamethasone in diabetic retinopathy (MERIT): a pilot study
por: Chhablani J, et al.
Publicado: (2018)

Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series
por: Singer MA, et al.
Publicado: (2016)

Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
por: Brooks CC, et al.
Publicado: (2020)

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
por: Laine I, et al.
Publicado: (2017)

Anti-inflammatory drug-eluting implant model system to prevent wear particle-induced periprosthetic osteolysis
por: Rivera MC, et al.
Publicado: (2019)

Longstanding refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7 mg dexamethasone implants
por: Brynskov T, et al.
Publicado: (2013)

Is There a Difference in the Resonance Frequency Values Obtained Directly on the Implants and Abutments?
por: Pozzer,Leandro, et al.
Publicado: (2015)

Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
por: Karttunen T, et al.
Publicado: (2019)

Outcomes of Epiretinal Membrane Removal Utilizing Triamcinolone Acetonide Visualization and Internal Limiting Membrane Forceps
por: Asahi MG, et al.
Publicado: (2020)

Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review
por: Wallsh J, et al.
Publicado: (2020)

Transdermal permeability of triamcinolone acetonide lipid nanoparticles
por: Qin ZM, et al.
Publicado: (2019)

Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study
por: Lam WC, et al.
Publicado: (2015)

Long-Term Outcomes of Macular Hole Repair with Triamcinolone Acetonide Visualization
por: Wallsh J, et al.
Publicado: (2021)

Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
por: Michalska-Małecka K, et al.
Publicado: (2016)

The relative effects of Ca and Mg ions on MSC osteogenesis in the surface modification of microrough Ti implants
por: Park JW, et al.
Publicado: (2019)